Published Date: 15 Aug 2025
The human papillomavirus (HPV) can cause six types of cancer. It's responsible for almost all cervical cancer cases. HPV now causes the majority of oropharyngeal (throat) cancers. It can also cause anal, vaginal, vulvar and ...
Read Full NewsNew UBC Okanagan research shows that exercise can do more than improve the strength and cardiovascular endurance of women who have survived breast cancer.
UCLA scientists, together with a team of international collaborators, have identified a promising new treatment strategy that can detect, kill and reprogram aggressive, treatment-resistant tumors like osteosarcomas and glioblastoma.
A research team led by Cancer Center at Illinois (CCIL) member Hua Wang has published new research detailing a new mRNA cancer vaccine platform. The study introduces an immune cell homing hydrogel-based platform designed ...
1.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
2.
Improved end-of-life conversations for cancer patients are identified by a new study.
3.
In early dementia, SSRIs enhance cognition and major depression.
4.
More pain, more gain? New biopsy technique found to improve prostate cancer detection
5.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
1.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
2.
Understanding Melanoma: From Diagnosis to Healing and Excision in Denver
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
The Statistical Evolution of Cancer Staging and Its Precision Impact on Prognosis and Therapy in Cancer Staging 2025
5.
PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
2.
Navigating the Complexities of Ph Negative ALL - Part X
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation